Monthly Archives: August 2021
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines
The effectiveness and safety of vaccinations can be altered by immunosuppressive therapies, and perhaps by inflammatory bowel disease (IBD) itself. These recommendations developed by the Canadian Association of Gastroenterology and endorsed by the Amer… Continue reading
Posted in News
Comments Off on Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines
713e Longitudinal Analysis in A HNF4AΔIEC Mouse Colitis Model Reveals that Preclinical Flaring is Associated with Increased Akkermansia muciniphila Levels in the Gut Microbiome
As inflammatory bowel diseases (IBD) develop, the host’s homeostatic relationship with their microbiota changes. Early “preclinical” stages of colitis are relatively understudied, especially with respect to host-microbiota interactions. Intestinal epit… Continue reading
Posted in News
Comments Off on 713e Longitudinal Analysis in A HNF4AΔIEC Mouse Colitis Model Reveals that Preclinical Flaring is Associated with Increased Akkermansia muciniphila Levels in the Gut Microbiome
713f Histologic Activity in Ulcerative Colitis Patients Achieving Endoscopic Healing is Associated with Higher Rate of Relapse and a Distinct Mucosal Microbial and Transcriptional Profile
Histologic remission (HR) in ulcerative colitis (UC) has been associated with better clinical outcomes. However, this therapeutic target is hard to achieve with the available medications. We aim to assess the relapse-free survival (RFS) of patients wit… Continue reading
Posted in News
Comments Off on 713f Histologic Activity in Ulcerative Colitis Patients Achieving Endoscopic Healing is Associated with Higher Rate of Relapse and a Distinct Mucosal Microbial and Transcriptional Profile
Information for Authors and Readers
Gastroenterology is the premiere journal in the field of gastrointestinal disease and is led by an internationally renowned board of editors. As the official journal of the AGA Institute, Gastroenterology delivers up-to-date and authoritative coverage … Continue reading
Posted in News
Comments Off on Information for Authors and Readers
713a Mining the Gut Microbiota for Novel Procarcinogenic Microbes Reveals Clostridioides difficile as a Driver of Colonic Tumorigenesis
Microbial studies in colorectal cancer (CRC) have largely focused on three species: colibactin-producing E. coli, enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum. However, not all CRC patients harbor these organisms, suggesting that e… Continue reading
Posted in News
Comments Off on 713a Mining the Gut Microbiota for Novel Procarcinogenic Microbes Reveals Clostridioides difficile as a Driver of Colonic Tumorigenesis
AGA Clinical Practice Update on Strategies to Improve Quality of Screening and Surveillance Colonoscopy: Expert Review
The purpose of this American Gastroenterological Association Institute Clinical Practice Update was to review the available evidence and provide best practice advice regarding strategies to improve the quality of screening and surveillance colonoscopy…. Continue reading
Posted in News
Comments Off on AGA Clinical Practice Update on Strategies to Improve Quality of Screening and Surveillance Colonoscopy: Expert Review
775c A Phase 2 Randomized Controlled Trial Demonstrating the Efficacy and Safety of Shr0302, A Selective JAK1 Inhibitor for the Treatment of Moderate to Severe Ulcerative Colitis Patients.
SHR0302 is a selective JAK1 inhibitor. A global, randomized, placebo-controlled phase 2 study (AMBER2; NCT03675477) consisting of an 8-week induction + 8-week extension period, was conducted to evaluate the efficacy and safety of SHR0302 in moderate to… Continue reading
Posted in News
Comments Off on 775c A Phase 2 Randomized Controlled Trial Demonstrating the Efficacy and Safety of Shr0302, A Selective JAK1 Inhibitor for the Treatment of Moderate to Severe Ulcerative Colitis Patients.